Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70071 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Alina N Saidi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Naltrexone, Obesity, Overweight, Liver Cirrhosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is prevalent among individuals with overweight or obesity and type 2 diabetes (T2DM), increasing the risk for liver‐related and cardiovascular complications. Lifestyle changes to reduce body weight are the primary intervention to decrease the risk of MASLD and liver fibrosis. This study aimed to evaluate the impact of a pharmacological intervention with naltrexone/bupropion (NB) on hepatic steatosis and fibrosis risk in patients with T2DM using non‐invasive tests. Materials and Methods In this post hoc analysis of a 56‐week, randomized, double‐blind, placebo‐controlled trial 505 adults with T2DM and overweight or obesity were randomized to either NB or placebo (2:1), both combined with structured lifestyle counselling. Hepatic outcomes were measured using the Hepatic Steatosis Index (HSI), Metabolic Dysfunction‐Associated Fibrosis‐5 (MAF‐5) and Fibrosis‐4 (FIB‐4) indices. Changes in liver‐related indices were analysed by treatment arm and weight loss strata (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
- Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
- Julius Center for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Julius Clinical, Zeist, The Netherlands.
- Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
- Department of Cardiology, Amphia Hospital, Breda, The Netherlands.
ORCID-Profile: Alina N Saidi
Zitieren
APA
Saidi, A. N., Konings, L. A. M., Dietvorst, C. A. W., de Jong, V. D., Brouwer, W. P., van der Lelij, A. J., Alings, M., van Wenum, M., Rauh, S. P., Xu, W., & Castro Cabezas, M. (2025). Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70071
Vancouver
Saidi AN, Konings LAM, Dietvorst CAW, de Jong VD, Brouwer WP, van der Lelij AJ, et al. Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70071
BibTeX
@article{Saidi2025,
author = {Saidi, Alina N and Konings, Laura A M and Dietvorst, Carmen A W and de Jong, Vivian D and Brouwer, Willem Pieter and van der Lelij, Aart-Jan and Alings, Marco and van Wenum, Martien and Rauh, Simone P and Xu, Weiwei and Castro Cabezas, Manuel},
title = {Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo‐controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70071}
}
EUVIMED